Huonslab Co., Ltd., the research and development subsidiary of KOSDAQ-listed Huons Global Co., Ltd. (KOSDAQ: 084110), has secured a patent covering subcutaneous antibody-drug conjugate formulations incorporating its recombinant human hyaluronidase-based HyDIFFUZE platform. The patent adds an intellectual property layer around Huonslab’s attempt to convert complex oncology biologics that are normally delivered through intravenous infusion into high-concentration subcutaneous formulations.
The development is commercially relevant because antibody-drug conjugates, or ADCs, have emerged as one of oncology’s most heavily invested therapeutic classes, yet every globally approved ADC continues to be administered intravenously. Subcutaneous delivery could shorten administration times and reduce dependence on infusion capacity, but ADCs are substantially more difficult to reformulate than conventional monoclonal antibodies because the antibody, linker and cytotoxic payload must all remain stable during manufacturing, storage and absorption.
Huonslab’s patent therefore addresses a legitimate and timely formulation problem. It does not, however, establish that a HyDIFFUZE-enabled ADC is clinically effective, safer than intravenous treatment or ready for regulatory submission. The supporting evidence disclosed to date consists primarily of preclinical pharmacokinetic studies in rats, while the broader field still lacks mature human comparisons of intravenous and subcutaneous ADC administration.
What exactly does the Huonslab ADC formulation patent attempt to protect?
The patent covers pharmaceutical formulations that combine an antibody-drug conjugate with recombinant human hyaluronidase PH20 for subcutaneous administration. Its claims extend across a range of ADC concentrations, formulation components and enzyme concentrations rather than being limited to a single proprietary oncology drug.
The published patent document identifies ADC concentrations ranging from 20 milligrams per millilitre to 240 milligrams per millilitre, including a narrower high-concentration range beginning at 50 milligrams per millilitre. It also describes recombinant human hyaluronidase concentrations from 1,000 to 10,000 units per millilitre and injection volumes potentially ranging from 0.5 millilitres to 25 millilitres.
The document specifically discusses formulations involving trastuzumab deruxtecan, trastuzumab emtansine and sacituzumab govitecan. It also refers more broadly to ADCs targeting HER2, Trop-2, CD33, CD22, CD30, CD79B, Nectin-4, BCMA, CD19 and folate receptor alpha. These references describe the potential scope of the invention and experimental models. They do not indicate that Huonslab owns, controls or has obtained development rights to the commercial ADC products associated with those molecules.
A related Patent Cooperation Treaty publication, WO2026142238A1, was published on July 2, 2026. The document describes buffers, surfactants, stabilisers and viscosity-reducing agents intended to preserve ADC stability and maintain an injectable viscosity under refrigerated conditions. Succinate and sodium phosphate buffers feature prominently in the disclosed formulations.
This formulation detail matters because a commercially useful subcutaneous ADC cannot simply be produced by adding hyaluronidase to an intravenous product. The drug must remain chemically and physically stable at a much higher concentration, retain an acceptable drug-to-antibody ratio and avoid aggregation, precipitation or linker degradation during storage and administration.
Why does subcutaneous delivery remain technically difficult for antibody-drug conjugates?
The subcutaneous space limits the volume that can be administered comfortably without an enabling technology. That creates pressure to formulate biologics at high concentrations, which can increase viscosity, aggregation and instability. ADCs add further complications because their cytotoxic payloads and linkers can make the molecules more hydrophobic and less stable than unconjugated antibodies.
A June 2026 review in Antibody Therapeutics found that most approved ADCs are supplied as freeze-dried products rather than ready-to-use liquids. Freeze-drying helps control degradation, but it also complicates the development of concentrated liquid products suitable for straightforward subcutaneous injection.
The clinical dose can create an equally difficult mathematical problem. The review calculated that converting a 6.4 milligram-per-kilogram trastuzumab deruxtecan regimen for a 75-kilogram patient into a two-millilitre injection could require a concentration of approximately 240 milligrams per millilitre, even before accounting for incomplete subcutaneous bioavailability. Larger-volume administration supported by hyaluronidase may reduce the concentration requirement, but it introduces its own formulation, device and administration-time considerations.
ADC payloads also raise local tolerability concerns that do not apply to ordinary antibodies in the same way. Slow absorption, local degradation or premature payload release could expose healthy tissue near the injection site to a potent cytotoxic compound. Animal research with some monomethyl auristatin E-based ADCs has shown reduced systemic exposure and significant injection-site injury after subcutaneous administration, although results vary according to the payload and molecular design.
Hyaluronidase may improve dispersion by temporarily breaking down hyaluronan within subcutaneous tissue. That could allow larger volumes and accelerate movement away from the injection site. It cannot by itself guarantee linker stability, complete bioavailability, adequate tumour exposure or acceptable local tolerability.
How persuasive are Huonslab’s preclinical pharmacokinetic findings?
Huonslab presented preclinical HyDIFFUZE findings at the 2026 annual meeting of the American Society for Clinical Pharmacology and Therapeutics. The company evaluated 11 monoclonal antibodies and three ADCs in Sprague-Dawley rats, comparing HyDIFFUZE-containing formulations with corresponding formulations that did not contain the recombinant hyaluronidase.
The company reported that HyDIFFUZE formulations produced exposure, measured by area under the concentration-time curve, ranging from 116% to 162% of the comparator formulations. Maximum plasma concentrations ranged from 113% to 170% of the non-HyDIFFUZE comparators. Huonslab also reported that some reduced-dose antibody formulations achieved exposure broadly comparable to higher-dose formulations without HyDIFFUZE.
The patent provides more molecule-specific findings. In rat studies involving concentrated sacituzumab govitecan formulations, adding HyDIFFUZE was associated with increases in both overall exposure and maximum concentration. The disclosed experiments also examined trastuzumab deruxtecan and trastuzumab emtansine formulations at concentrations of up to 120 milligrams per millilitre.
These findings support the biological rationale for further development, but they remain preclinical pharmacokinetic evidence. Small animal studies cannot determine whether an ADC formulation will produce equivalent tumour exposure, maintain efficacy, avoid clinically significant injection-site reactions or deliver an acceptable safety profile in patients.
Differences between animal and human subcutaneous tissue, lymphatic absorption and drug metabolism are particularly important. Independent researchers have warned that animal models can have limited predictive value for human subcutaneous bioavailability, especially for ADCs with multiple measurable components, including total antibody, conjugated ADC, unconjugated antibody and free payload.
Where does HyDIFFUZE sit in the emerging race to convert ADCs from IV to SC?
Huonslab is not pursuing the subcutaneous ADC opportunity in isolation. A recent industry review identified 12 ADC programmes that had entered preclinical or early clinical evaluation through the subcutaneous route, with eight programmes described as active at the time of publication.
The competitive field includes molecular redesign, high-concentration liquid formulations, polymer-based hydrogels and hyaluronidase-assisted delivery. Several developers are attempting to design new ADCs specifically for subcutaneous administration rather than adapting existing intravenous products after development.
AstraZeneca PLC and Daiichi Sankyo Co., Ltd. are also evaluating a subcutaneous formulation of trastuzumab deruxtecan using Alteogen Inc.’s ALT-B4 recombinant hyaluronidase technology. The Phase 1 programme is especially relevant to Huonslab because it may provide some of the first human evidence showing how a commercially established ADC behaves when delivered subcutaneously with a hyaluronidase platform.
Other strategies may compete without using hyaluronidase. Alphamab Oncology’s JSKN033 combines an ADC with a PD-L1-targeted antibody in a high-concentration subcutaneous formulation. Early clinical development has demonstrated feasibility, although injection-site reactions have been common, reinforcing the gap between technical injectability and an optimised patient experience.
Huonslab’s positioning will consequently depend on whether its platform can show advantages in formulation flexibility, manufacturability, licensing economics or molecule compatibility. A broad patent may strengthen partnering discussions, but pharmaceutical companies will require molecule-specific data before committing valuable oncology assets to an external delivery platform.
Why does HYDIZYME’s regulatory progress matter to HyDIFFUZE platform credibility?
Huonslab is separately seeking South Korean approval for HYDIZYME, its standalone recombinant human hyaluronidase product, also known by the development code HLB3-002. The company submitted a biologics licence application to the Ministry of Food and Drug Safety in December 2025 and has said it is targeting a decision during the second half of 2026.
The application was supported by a randomised, double-blind and placebo-controlled Phase 1 study involving 243 healthy volunteers. Huonslab reported that the programme found no serious adverse events, although a full independent publication of the complete dataset would provide a stronger basis for evaluating safety, immunogenicity and allergenicity.
An approval for standalone HYDIZYME would not authorise any HyDIFFUZE-enabled ADC combination. Each co-formulated oncology product would still require formulation development, nonclinical testing, clinical pharmacology studies and an appropriate regulatory programme.
Nevertheless, approval could validate important elements of Huonslab’s manufacturing process, analytical controls and recombinant hyaluronidase supply chain. Platform partners are likely to examine enzyme purity, batch consistency, stability, immunogenicity risk and commercial-scale manufacturing capacity before evaluating HyDIFFUZE for an ADC programme.
What must Huonslab prove before the patent becomes a commercial asset?
The first major requirement is a formulation that remains stable for a commercially realistic shelf life. Patent examples involving several weeks of refrigerated storage provide an initial technical foundation, but late-stage development normally requires substantially longer stability packages, validated analytical methods and manufacturing data from representative commercial-scale batches.
The second requirement is human pharmacokinetic comparability. Huonslab or a partner will need to show that subcutaneous administration achieves sufficient exposure to the intact ADC while controlling free payload, unconjugated antibody and other relevant analytes. Matching total antibody exposure alone may not be enough for a regulator or development partner.
The third requirement is local and systemic safety. The development programme will need careful monitoring of injection-site pain, erythema, swelling, tissue injury and delayed reactions, alongside the established toxicities associated with the underlying ADC. A lower peak concentration could theoretically improve some systemic effects, but that possibility must be demonstrated rather than assumed from animal pharmacokinetics.
Commercialisation will also require a viable administration device, practical injection duration, acceptable volume and a convincing health-economic case. Hospitals may value shorter chair time, but the economic benefit will depend on product pricing, drug wastage, staffing requirements, observation periods and whether treatment can move from major infusion centres into community settings.
What does the announcement mean for Huons Global investor sentiment?
Huonslab is not independently listed, meaning market exposure to the platform sits indirectly through Huons Global Co., Ltd. Recent trading in the parent company has been volatile. Huons Global closed at KRW 23,800 on July 22, 2026, after falling 11.1% on July 20 and gaining 10.3% on July 15. The available price history also shows that the shares remained substantially below the levels recorded earlier in 2026.
The ADC patent is best viewed as a long-term platform signal rather than a near-term revenue catalyst. Huonslab has not disclosed a commercial ADC partner, human study timeline, licensing payment or development agreement connected with the patented formulations.
Near-term investor attention is therefore more likely to remain focused on the Ministry of Food and Drug Safety review of HYDIZYME. A regulatory decision could provide a clearer test of Huonslab’s manufacturing and product-development execution, while any subsequent partnership involving a named ADC would offer stronger evidence that external developers consider the platform technically and commercially credible.
The patent gives Huonslab a potentially useful negotiating asset at a time when subcutaneous ADC development is moving from theoretical interest into early clinical testing. Its real value will depend on what follows: durable formulation stability, reproducible manufacturing, human pharmacokinetic data, manageable injection-site tolerability and a partner willing to place a clinically meaningful ADC programme behind HyDIFFUZE.
